GERN; $2.32 flat below SMA 200, 50 & 20 following strong downward trend line from Dec 2013.($2.00 by Sept.1 ) Shorts 15% Target Price $4.13 insider trading several smaller sells in April/May one large purchase by BoD member in May. 1/6th average vol.
ASTY; $2.40 down $.03 average vol.
INCY WINCY SPIDER.
INCY; $50.65 up $.46 below SMA 200, 50 in gradual upward channel. Shorts 6.5% Target price $70.77 insider trading consists of options being exercised as sales. no purchases. 7/11ths average vol
The last partial hold release on the MF MAYO trial in June was preceded with a spike in vol, and increase in SP due to seepage. Neither are present this time yet.
I agree E2W the bol bands are tightening around my neck meaning it's getting harder to breath. A big move in either direction; either I'll drop dead from asphyxiation or break loose from this noose and breath a lung full of fresh air.
gibberish or not the previous two short calls by Bulls was accurate. Their last 3 buy signals were not.
Jack I'd be the first to state that Geron has sufficient data from other clinical trials that could easily satisfy the FDA 's safety requirement. However the one patient's death in the ET & PV trials that triggered this full FDA clinical hold was suspiciously timed after the first in class efficacy CR data from the MAYO's MF study was made available. The ET/PV trials patient who died from complications due to liver failure was determined to be caused by a pre existing liver condition, hepatitus and not Imet.
INCY's resulting extended non competitive time line is what I have issue with as with GERN's current SP.
I got it with your Motesenib water skeeter analogy.....the Jesus bug is but an illusion compared its sodium based miracle making cousin Imetelstat sodium.
Appreciate the clarification Box.
Thanx from the bottom of my pond.
Maybe the answer is not sealed in the Mayo but rather in the Skippy jar.
End you seem well researched on Imetelstat. I asked the board bfr. if anyone could clarify the cmpd's listed on the NCBI's PUB CHEM site under the same heading.
Also known as: Motesanib; AMG-706; 453562-69-1; AMG 706; CHEBI:51098; N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
Molecular Formula: C22H23N5O Molecular Weight: 373.45092 InChIKey: RAHBGWKEPAQNFF-UHFFFAOYSA-N"
...didn't the FDA have enough data from Geron's two years of breast cancer trials to access the LFT reversibility issue? The MAYO's MF was cleared for LFR concerns. Why hold up the drug on a proof in concept trial? This smacks of Copenhagen's Red Herring fish market.
Bears "Signal Update
Our system’s recommendation today is to SHORT. The BEARISH HARAMI CROSS pattern finally received a confirmation because the prices crossed below the confirmation level which was at 2.3650, and our valid average selling price stands now at 2.3600. The previous BUY recommendation was issued on 08/08/2014, 12 days ago, when the stock price was 2.4350. Since then GERN has fallen by -3.08%"
Come on Chippy throw some acorns at them.
SIGA SAGA...got a few hrs?
I'll fill you in.
They lost twice in Delaware. Once more and they're out. Although I've been out a few yrs now.
great call on PTX Kitty. Wish I had loaded up instead of being hit head on by some ambulance chasers on a gerny. (((8=3(
Henrietta Lacks’ ‘Immortal’ Cells
In 1951, a scientist at Johns Hopkins Hospital in Baltimore, Maryland, created the first immortal human cell line with a tissue sample taken from a young black woman with cervical cancer. Those cells, called HeLa cells, quickly became invaluable to medical research—though their donor remained a mystery for decades.
Medical research has been practising it's research based on such methodology for over half a century. Why the big moral argument today?